Medexus Pharmaceuticals Statistics

Total Valuation

Medexus Pharmaceuticals has a market cap or net worth of 48.37 million. The enterprise value is 82.21 million.

Market Cap	48.37M
Enterprise Value	82.21M

Important Dates

The next estimated earnings date is Thursday, February 6, 2025.

Earnings Date	Feb 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+18.66%
Shares Change (QoQ)	+0.37%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	22.27M

Valuation Ratios

The trailing PE ratio is 21.08.

PE Ratio	21.08
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 4.69, with an EV/FCF ratio of 3.72.

EV / Earnings	35.82
EV / Sales	0.83
EV / EBITDA	4.69
EV / EBIT	6.82
EV / FCF	3.72

Financial Position

The company has a current ratio of 1.01, with a Debt / Equity ratio of 1.31.

Current Ratio	1.01
Quick Ratio	0.32
Debt / Equity	1.31
Debt / EBITDA	2.31
Debt / FCF	1.94
Interest Coverage	1.41

Financial Efficiency

Return on equity (ROE) is 8.42% and return on invested capital (ROIC) is 9.45%.

Return on Equity (ROE)	8.42%
Return on Assets (ROA)	5.14%
Return on Capital (ROIC)	9.45%
Revenue Per Employee	1.28M
Profits Per Employee	27,988
Employee Count	82
Asset Turnover	0.67
Inventory Turnover	1.40

Taxes

In the past 12 months, Medexus Pharmaceuticals has paid 318,981 in taxes.

Income Tax	318,981
Effective Tax Rate	303.85%

Stock Price Statistics

The stock price has increased by +31.47% in the last 52 weeks. The beta is 1.96, so Medexus Pharmaceuticals's price volatility has been higher than the market average.

Beta (5Y)	1.96
52-Week Price Change	+31.47%
50-Day Moving Average	1.81
200-Day Moving Average	1.56
Relative Strength Index (RSI)	48.70
Average Volume (20 Days)	9,776

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Medexus Pharmaceuticals had revenue of 104.76 million and earned 2.30 million in profits. Earnings per share was 0.09.

Revenue	104.76M
Gross Profit	60.61M
Operating Income	12.82M
Pretax Income	1.51M
Net Income	2.30M
EBITDA	18.48M
EBIT	12.82M
Earnings Per Share (EPS)	0.09

Full Income Statement

Balance Sheet

The company has 6.97 million in cash and 42.97 million in debt, giving a net cash position of -36.00 million.

Cash & Cash Equivalents	6.97M
Total Debt	42.97M
Net Cash	-36.00M
Net Cash Per Share	n/a
Equity (Book Value)	32.74M
Book Value Per Share	1.33
Working Capital	751,000

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 22.20 million and capital expenditures -75,000, giving a free cash flow of 22.12 million.

Operating Cash Flow	22.20M
Capital Expenditures	-75,000
Free Cash Flow	22.12M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 57.85%, with operating and profit margins of 12.24% and 2.19%.

Gross Margin	57.85%
Operating Margin	12.24%
Pretax Margin	1.45%
Profit Margin	2.19%
EBITDA Margin	17.64%
EBIT Margin	12.24%
FCF Margin	21.12%

Dividends & Yields

Medexus Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-18.66%
Shareholder Yield	-18.66%
Earnings Yield	4.60%
FCF Yield	n/a

Stock Splits

The last stock split was on December 19, 2018. It was a reverse split with a ratio of 0.0666666.

Last Split Date	Dec 19, 2018
Split Type	Reverse
Split Ratio	0.0666666

Scores

Medexus Pharmaceuticals has an Altman Z-Score of 0.61 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.61
Piotroski F-Score	3